Answers are grounded in this paper and cite their sources.
Guselkumab demonstrated superior efficacy compared with adalimumab and was well tolerated in patients with psoriasis through 1 year.
No takes yet. Share an insight, caveat, or question.
Blauvelt et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: